Acceleron Pharma Inc (XLRN.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||2015||Independent Chairman of the Board|
|47||2016||President, Chief Executive Officer, Director|
|60||2010||Chief Financial Officer, Senior Vice President, Treasurer|
|46||2018||Executive Vice President, Chief Business Officer, Secretary|
|62||2015||Executive Vice President and Chief Medical Officer|
- BRIEF-Acceleron Begins Phase 2 Trial Of Pulmonary Arterial Hypertension Treatment
- BRIEF-Acceleron Reports Q1 Loss Per Share $0.58
- BRIEF-Acceleron Receives FDA Fast Track Designation For Ace-083 In Facioscapulohumeral Muscular Dystrophy
- BRIEF-Acceleron Pharma Q4 Loss Per Share $0.62
- BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018